aluates Reports

$ 0.0

Automative

Global Retinal Drugs and Biologics Market Research Report 2025

Published Date: September 2025

Report Code: QYRE-Auto-34K10975

Global Retinal Drugs and Biologics Market Research Report 2022

BUY CHAPTERS

Global Retinal Drugs and Biologics Market Research Report 2025

Code: QYRE-Auto-34K10975

Report

September 2025

Pages:91

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Allergan plc

AbbVie

Alimera Sciences

Janssen Biotech

Swedish Orphan Biovitrum

Roche

Bristol–Myers Squibb

Genzyme

Genentech Inc

Ocular Therapeutix

Bausch & Lomb

UCBCares

Retinal Drugs and Biologics Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Retinal Drugs and Biologics Market

The global market for Retinal Drugs and Biologics was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Retinal Drugs and Biologics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Retinal Drugs and Biologics.

The Retinal Drugs and Biologics market size, estimations, and forecasts are provided in terms of sales volume (K MT) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Retinal Drugs and Biologics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Retinal Drugs and Biologics manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Retinal Drugs and Biologics Market Report

Report Metric	Details
Report Name	Retinal Drugs and Biologics Market
CAGR	5%
Segment by Type	Age Related Macular Degeneration Diabetic Retinopathy Ocular Inflammatory Disease (Uveitis) Macular Hole
Segment by Application	Hospitals Clinics Others
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	ALLERGAN, AbbVie, Alimera Sciences, Janssen Biotech, Swedish Orphan Biovitrum, Roche, Bristol-Myers Squibb, Genzyme, Genentech, OCULAR THERAPEUTIX, Bausch & Lomb, UCBCares
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Retinal Drugs and Biologics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Retinal Drugs and Biologics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Retinal Drugs and Biologics Market report?

Ans: The main players in the Retinal Drugs and Biologics Market are ALLERGAN, AbbVie, Alimera Sciences, Janssen Biotech, Swedish Orphan Biovitrum, Roche, Bristol-Myers Squibb, Genzyme, Genentech, OCULAR THERAPEUTIX, Bausch & Lomb, UCBCares

What are the Application segmentation covered in the Retinal Drugs and Biologics Market report?

Ans: The Applications covered in the Retinal Drugs and Biologics Market report are Hospitals, Clinics, Others

What are the Type segmentation covered in the Retinal Drugs and Biologics Market report?

Ans: The Types covered in the Retinal Drugs and Biologics Market report are Age Related Macular Degeneration, Diabetic Retinopathy, Ocular Inflammatory Disease (Uveitis), Macular Hole

1 Retinal Drugs and Biologics Market Overview

1.1 Product Definition

1.2 Retinal Drugs and Biologics by Type

1.2.1 Global Retinal Drugs and Biologics Market Value Comparison by Type (2024 VS 2031)

1.2.2 Age Related Macular Degeneration

1.2.3 Diabetic Retinopathy

1.2.4 Ocular Inflammatory Disease (Uveitis)

1.2.5 Macular Hole

1.3 Retinal Drugs and Biologics by Application

1.3.1 Global Retinal Drugs and Biologics Market Value by Application (2024 VS 2031)

1.3.2 Hospitals

1.3.3 Clinics

1.3.4 Others

1.4 Global Retinal Drugs and Biologics Market Size Estimates and Forecasts

1.4.1 Global Retinal Drugs and Biologics Revenue 2020-2031

1.4.2 Global Retinal Drugs and Biologics Sales 2020-2031

1.4.3 Global Retinal Drugs and Biologics Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Retinal Drugs and Biologics Market Competition by Manufacturers

2.1 Global Retinal Drugs and Biologics Sales Market Share by Manufacturers (2020-2025)

2.2 Global Retinal Drugs and Biologics Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Retinal Drugs and Biologics Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Retinal Drugs and Biologics, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Retinal Drugs and Biologics, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Retinal Drugs and Biologics, Product Type & Application

2.7 Global Key Manufacturers of Retinal Drugs and Biologics, Date of Enter into This Industry

2.8 Global Retinal Drugs and Biologics Market Competitive Situation and Trends

2.8.1 Global Retinal Drugs and Biologics Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Retinal Drugs and Biologics Players Market Share by Revenue

2.8.3 Global Retinal Drugs and Biologics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Retinal Drugs and Biologics Market Scenario by Region

3.1 Global Retinal Drugs and Biologics Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Retinal Drugs and Biologics Sales by Region: 2020-2031

3.2.1 Global Retinal Drugs and Biologics Sales by Region: 2020-2025

3.2.2 Global Retinal Drugs and Biologics Sales by Region: 2026-2031

3.3 Global Retinal Drugs and Biologics Revenue by Region: 2020-2031

3.3.1 Global Retinal Drugs and Biologics Revenue by Region: 2020-2025

3.3.2 Global Retinal Drugs and Biologics Revenue by Region: 2026-2031

3.4 North America Retinal Drugs and Biologics Market Facts & Figures by Country

3.4.1 North America Retinal Drugs and Biologics Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Retinal Drugs and Biologics Sales by Country (2020-2031)

3.4.3 North America Retinal Drugs and Biologics Revenue by Country (2020-2031)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Retinal Drugs and Biologics Market Facts & Figures by Country

3.5.1 Europe Retinal Drugs and Biologics Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Retinal Drugs and Biologics Sales by Country (2020-2031)

3.5.3 Europe Retinal Drugs and Biologics Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Retinal Drugs and Biologics Market Facts & Figures by Region

3.6.1 Asia Pacific Retinal Drugs and Biologics Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Retinal Drugs and Biologics Sales by Region (2020-2031)

3.6.3 Asia Pacific Retinal Drugs and Biologics Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America Retinal Drugs and Biologics Market Facts & Figures by Country

3.7.1 Latin America Retinal Drugs and Biologics Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Retinal Drugs and Biologics Sales by Country (2020-2031)

3.7.3 Latin America Retinal Drugs and Biologics Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Retinal Drugs and Biologics Market Facts & Figures by Country

3.8.1 Middle East and Africa Retinal Drugs and Biologics Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Retinal Drugs and Biologics Sales by Country (2020-2031)

3.8.3 Middle East and Africa Retinal Drugs and Biologics Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 U.A.E

4 Segment by Type

4.1 Global Retinal Drugs and Biologics Sales by Type (2020-2031)

4.1.1 Global Retinal Drugs and Biologics Sales by Type (2020-2025)

4.1.2 Global Retinal Drugs and Biologics Sales by Type (2026-2031)

4.1.3 Global Retinal Drugs and Biologics Sales Market Share by Type (2020-2031)

4.2 Global Retinal Drugs and Biologics Revenue by Type (2020-2031)

4.2.1 Global Retinal Drugs and Biologics Revenue by Type (2020-2025)

4.2.2 Global Retinal Drugs and Biologics Revenue by Type (2026-2031)

4.2.3 Global Retinal Drugs and Biologics Revenue Market Share by Type (2020-2031)

4.3 Global Retinal Drugs and Biologics Price by Type (2020-2031)

5 Segment by Application

5.1 Global Retinal Drugs and Biologics Sales by Application (2020-2031)

5.1.1 Global Retinal Drugs and Biologics Sales by Application (2020-2025)

5.1.2 Global Retinal Drugs and Biologics Sales by Application (2026-2031)

5.1.3 Global Retinal Drugs and Biologics Sales Market Share by Application (2020-2031)

5.2 Global Retinal Drugs and Biologics Revenue by Application (2020-2031)

5.2.1 Global Retinal Drugs and Biologics Revenue by Application (2020-2025)

5.2.2 Global Retinal Drugs and Biologics Revenue by Application (2026-2031)

5.2.3 Global Retinal Drugs and Biologics Revenue Market Share by Application (2020-2031)

5.3 Global Retinal Drugs and Biologics Price by Application (2020-2031)

6 Key Companies Profiled

6.1 ALLERGAN

6.1.1 ALLERGAN Company Information

6.1.2 ALLERGAN Description and Business Overview

6.1.3 ALLERGAN Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2020-2025)

6.1.4 ALLERGAN Retinal Drugs and Biologics Product Portfolio

6.1.5 ALLERGAN Recent Developments/Updates

6.2 AbbVie

6.2.1 AbbVie Company Information

6.2.2 AbbVie Description and Business Overview

6.2.3 AbbVie Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2020-2025)

6.2.4 AbbVie Retinal Drugs and Biologics Product Portfolio

6.2.5 AbbVie Recent Developments/Updates

6.3 Alimera Sciences

6.3.1 Alimera Sciences Company Information

6.3.2 Alimera Sciences Description and Business Overview

6.3.3 Alimera Sciences Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Alimera Sciences Retinal Drugs and Biologics Product Portfolio

6.3.5 Alimera Sciences Recent Developments/Updates

6.4 Janssen Biotech

6.4.1 Janssen Biotech Company Information

6.4.2 Janssen Biotech Description and Business Overview

6.4.3 Janssen Biotech Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Janssen Biotech Retinal Drugs and Biologics Product Portfolio

6.4.5 Janssen Biotech Recent Developments/Updates

6.5 Swedish Orphan Biovitrum

6.5.1 Swedish Orphan Biovitrum Company Information

6.5.2 Swedish Orphan Biovitrum Description and Business Overview

6.5.3 Swedish Orphan Biovitrum Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2020-2025)

6.5.4 Swedish Orphan Biovitrum Retinal Drugs and Biologics Product Portfolio

6.5.5 Swedish Orphan Biovitrum Recent Developments/Updates

6.6 Roche

6.6.1 Roche Company Information

6.6.2 Roche Description and Business Overview

6.6.3 Roche Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2020-2025)

6.6.4 Roche Retinal Drugs and Biologics Product Portfolio

6.6.5 Roche Recent Developments/Updates

6.7 Bristol-Myers Squibb

6.7.1 Bristol-Myers Squibb Company Information

6.7.2 Bristol-Myers Squibb Description and Business Overview

6.7.3 Bristol-Myers Squibb Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2020-2025)

6.7.4 Bristol-Myers Squibb Retinal Drugs and Biologics Product Portfolio

6.7.5 Bristol-Myers Squibb Recent Developments/Updates

6.8 Genzyme

6.8.1 Genzyme Company Information

6.8.2 Genzyme Description and Business Overview

6.8.3 Genzyme Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2020-2025)

6.8.4 Genzyme Retinal Drugs and Biologics Product Portfolio

6.8.5 Genzyme Recent Developments/Updates

6.9 Genentech

6.9.1 Genentech Company Information

6.9.2 Genentech Description and Business Overview

6.9.3 Genentech Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2020-2025)

6.9.4 Genentech Retinal Drugs and Biologics Product Portfolio

6.9.5 Genentech Recent Developments/Updates

6.10 OCULAR THERAPEUTIX

6.10.1 OCULAR THERAPEUTIX Company Information

6.10.2 OCULAR THERAPEUTIX Description and Business Overview

6.10.3 OCULAR THERAPEUTIX Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2020-2025)

6.10.4 OCULAR THERAPEUTIX Retinal Drugs and Biologics Product Portfolio

6.10.5 OCULAR THERAPEUTIX Recent Developments/Updates

6.11 Bausch & Lomb

6.11.1 Bausch & Lomb Company Information

6.11.2 Bausch & Lomb Description and Business Overview

6.11.3 Bausch & Lomb Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2020-2025)

6.11.4 Bausch & Lomb Retinal Drugs and Biologics Product Portfolio

6.11.5 Bausch & Lomb Recent Developments/Updates

6.12 UCBCares

6.12.1 UCBCares Company Information

6.12.2 UCBCares Description and Business Overview

6.12.3 UCBCares Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2020-2025)

6.12.4 UCBCares Retinal Drugs and Biologics Product Portfolio

6.12.5 UCBCares Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Retinal Drugs and Biologics Industry Chain Analysis

7.2 Retinal Drugs and Biologics Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Retinal Drugs and Biologics Production Mode & Process Analysis

7.4 Retinal Drugs and Biologics Sales and Marketing

7.4.1 Retinal Drugs and Biologics Sales Channels

7.4.2 Retinal Drugs and Biologics Distributors

7.5 Retinal Drugs and Biologics Customer Analysis

8 Retinal Drugs and Biologics Market Dynamics

8.1 Retinal Drugs and Biologics Industry Trends

8.2 Retinal Drugs and Biologics Market Drivers

8.3 Retinal Drugs and Biologics Market Challenges

8.4 Retinal Drugs and Biologics Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Allergan plc

AbbVie

Alimera Sciences

Janssen Biotech

Swedish Orphan Biovitrum

Roche

Bristol–Myers Squibb

Genzyme

Genentech Inc

Ocular Therapeutix

Bausch & Lomb

UCBCares

List of Tables

Table 1. Global Retinal Drugs and Biologics Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Retinal Drugs and Biologics Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Retinal Drugs and Biologics Market Competitive Situation by Manufacturers in 2024

Table 4. Global Retinal Drugs and Biologics Sales (K MT) of Key Manufacturers (2020-2025)

Table 5. Global Retinal Drugs and Biologics Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Retinal Drugs and Biologics Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Retinal Drugs and Biologics Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Retinal Drugs and Biologics Average Price (USD/MT) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Retinal Drugs and Biologics, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Retinal Drugs and Biologics, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Retinal Drugs and Biologics, Product Type & Application

Table 12. Global Key Manufacturers of Retinal Drugs and Biologics, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Retinal Drugs and Biologics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Retinal Drugs and Biologics as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Retinal Drugs and Biologics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Retinal Drugs and Biologics Sales by Region (2020-2025) & (K MT)

Table 18. Global Retinal Drugs and Biologics Sales Market Share by Region (2020-2025)

Table 19. Global Retinal Drugs and Biologics Sales by Region (2026-2031) & (K MT)

Table 20. Global Retinal Drugs and Biologics Sales Market Share by Region (2026-2031)

Table 21. Global Retinal Drugs and Biologics Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Retinal Drugs and Biologics Revenue Market Share by Region (2020-2025)

Table 23. Global Retinal Drugs and Biologics Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Retinal Drugs and Biologics Revenue Market Share by Region (2026-2031)

Table 25. North America Retinal Drugs and Biologics Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Retinal Drugs and Biologics Sales by Country (2020-2025) & (K MT)

Table 27. North America Retinal Drugs and Biologics Sales by Country (2026-2031) & (K MT)

Table 28. North America Retinal Drugs and Biologics Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Retinal Drugs and Biologics Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Retinal Drugs and Biologics Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Retinal Drugs and Biologics Sales by Country (2020-2025) & (K MT)

Table 32. Europe Retinal Drugs and Biologics Sales by Country (2026-2031) & (K MT)

Table 33. Europe Retinal Drugs and Biologics Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Retinal Drugs and Biologics Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Retinal Drugs and Biologics Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Retinal Drugs and Biologics Sales by Region (2020-2025) & (K MT)

Table 37. Asia Pacific Retinal Drugs and Biologics Sales by Region (2026-2031) & (K MT)

Table 38. Asia Pacific Retinal Drugs and Biologics Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Retinal Drugs and Biologics Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Retinal Drugs and Biologics Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Retinal Drugs and Biologics Sales by Country (2020-2025) & (K MT)

Table 42. Latin America Retinal Drugs and Biologics Sales by Country (2026-2031) & (K MT)

Table 43. Latin America Retinal Drugs and Biologics Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Retinal Drugs and Biologics Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Retinal Drugs and Biologics Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Retinal Drugs and Biologics Sales by Country (2020-2025) & (K MT)

Table 47. Middle East and Africa Retinal Drugs and Biologics Sales by Country (2026-2031) & (K MT)

Table 48. Middle East and Africa Retinal Drugs and Biologics Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Retinal Drugs and Biologics Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Retinal Drugs and Biologics Sales (K MT) by Type (2020-2025)

Table 51. Global Retinal Drugs and Biologics Sales (K MT) by Type (2026-2031)

Table 52. Global Retinal Drugs and Biologics Sales Market Share by Type (2020-2025)

Table 53. Global Retinal Drugs and Biologics Sales Market Share by Type (2026-2031)

Table 54. Global Retinal Drugs and Biologics Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Retinal Drugs and Biologics Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Retinal Drugs and Biologics Revenue Market Share by Type (2020-2025)

Table 57. Global Retinal Drugs and Biologics Revenue Market Share by Type (2026-2031)

Table 58. Global Retinal Drugs and Biologics Price (USD/MT) by Type (2020-2025)

Table 59. Global Retinal Drugs and Biologics Price (USD/MT) by Type (2026-2031)

Table 60. Global Retinal Drugs and Biologics Sales (K MT) by Application (2020-2025)

Table 61. Global Retinal Drugs and Biologics Sales (K MT) by Application (2026-2031)

Table 62. Global Retinal Drugs and Biologics Sales Market Share by Application (2020-2025)

Table 63. Global Retinal Drugs and Biologics Sales Market Share by Application (2026-2031)

Table 64. Global Retinal Drugs and Biologics Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Retinal Drugs and Biologics Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Retinal Drugs and Biologics Revenue Market Share by Application (2020-2025)

Table 67. Global Retinal Drugs and Biologics Revenue Market Share by Application (2026-2031)

Table 68. Global Retinal Drugs and Biologics Price (USD/MT) by Application (2020-2025)

Table 69. Global Retinal Drugs and Biologics Price (USD/MT) by Application (2026-2031)

Table 70. ALLERGAN Company Information

Table 71. ALLERGAN Description and Business Overview

Table 72. ALLERGAN Retinal Drugs and Biologics Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)

Table 73. ALLERGAN Retinal Drugs and Biologics Product

Table 74. ALLERGAN Recent Developments/Updates

Table 75. AbbVie Company Information

Table 76. AbbVie Description and Business Overview

Table 77. AbbVie Retinal Drugs and Biologics Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)

Table 78. AbbVie Retinal Drugs and Biologics Product

Table 79. AbbVie Recent Developments/Updates

Table 80. Alimera Sciences Company Information

Table 81. Alimera Sciences Description and Business Overview

Table 82. Alimera Sciences Retinal Drugs and Biologics Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)

Table 83. Alimera Sciences Retinal Drugs and Biologics Product

Table 84. Alimera Sciences Recent Developments/Updates

Table 85. Janssen Biotech Company Information

Table 86. Janssen Biotech Description and Business Overview

Table 87. Janssen Biotech Retinal Drugs and Biologics Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)

Table 88. Janssen Biotech Retinal Drugs and Biologics Product

Table 89. Janssen Biotech Recent Developments/Updates

Table 90. Swedish Orphan Biovitrum Company Information

Table 91. Swedish Orphan Biovitrum Description and Business Overview

Table 92. Swedish Orphan Biovitrum Retinal Drugs and Biologics Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)

Table 93. Swedish Orphan Biovitrum Retinal Drugs and Biologics Product

Table 94. Swedish Orphan Biovitrum Recent Developments/Updates

Table 95. Roche Company Information

Table 96. Roche Description and Business Overview

Table 97. Roche Retinal Drugs and Biologics Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)

Table 98. Roche Retinal Drugs and Biologics Product

Table 99. Roche Recent Developments/Updates

Table 100. Bristol-Myers Squibb Company Information

Table 101. Bristol-Myers Squibb Description and Business Overview

Table 102. Bristol-Myers Squibb Retinal Drugs and Biologics Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)

Table 103. Bristol-Myers Squibb Retinal Drugs and Biologics Product

Table 104. Bristol-Myers Squibb Recent Developments/Updates

Table 105. Genzyme Company Information

Table 106. Genzyme Description and Business Overview

Table 107. Genzyme Retinal Drugs and Biologics Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)

Table 108. Genzyme Retinal Drugs and Biologics Product

Table 109. Genzyme Recent Developments/Updates

Table 110. Genentech Company Information

Table 111. Genentech Description and Business Overview

Table 112. Genentech Retinal Drugs and Biologics Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)

Table 113. Genentech Retinal Drugs and Biologics Product

Table 114. Genentech Recent Developments/Updates

Table 115. OCULAR THERAPEUTIX Company Information

Table 116. OCULAR THERAPEUTIX Description and Business Overview

Table 117. OCULAR THERAPEUTIX Retinal Drugs and Biologics Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)

Table 118. OCULAR THERAPEUTIX Retinal Drugs and Biologics Product

Table 119. OCULAR THERAPEUTIX Recent Developments/Updates

Table 120. Bausch & Lomb Company Information

Table 121. Bausch & Lomb Description and Business Overview

Table 122. Bausch & Lomb Retinal Drugs and Biologics Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)

Table 123. Bausch & Lomb Retinal Drugs and Biologics Product

Table 124. Bausch & Lomb Recent Developments/Updates

Table 125. UCBCares Company Information

Table 126. UCBCares Description and Business Overview

Table 127. UCBCares Retinal Drugs and Biologics Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)

Table 128. UCBCares Retinal Drugs and Biologics Product

Table 129. UCBCares Recent Developments/Updates

Table 130. Key Raw Materials Lists

Table 131. Raw Materials Key Suppliers Lists

Table 132. Retinal Drugs and Biologics Distributors List

Table 133. Retinal Drugs and Biologics Customers List

Table 134. Retinal Drugs and Biologics Market Trends

Table 135. Retinal Drugs and Biologics Market Drivers

Table 136. Retinal Drugs and Biologics Market Challenges

Table 137. Retinal Drugs and Biologics Market Restraints

Table 138. Research Programs/Design for This Report

Table 139. Key Data Information from Secondary Sources

Table 140. Key Data Information from Primary Sources

Table 141. Authors List of This Report

List of Figures

Figure 1. Product Picture of Retinal Drugs and Biologics

Figure 2. Global Retinal Drugs and Biologics Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Retinal Drugs and Biologics Market Share by Type: 2024 & 2031

Figure 4. Age Related Macular Degeneration Product Picture

Figure 5. Diabetic Retinopathy Product Picture

Figure 6. Ocular Inflammatory Disease (Uveitis) Product Picture

Figure 7. Macular Hole Product Picture

Figure 8. Global Retinal Drugs and Biologics Market Value by Application (2020-2031) & (US$ Million)

Figure 9. Global Retinal Drugs and Biologics Market Share by Application: 2024 & 2031

Figure 10. Hospitals

Figure 11. Clinics

Figure 12. Others

Figure 13. Global Retinal Drugs and Biologics Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 14. Global Retinal Drugs and Biologics Market Size (2020-2031) & (US$ Million)

Figure 15. Global Retinal Drugs and Biologics Sales (2020-2031) & (K MT)

Figure 16. Global Retinal Drugs and Biologics Average Price (USD/MT) & (2020-2031)

Figure 17. Retinal Drugs and Biologics Report Years Considered

Figure 18. Retinal Drugs and Biologics Sales Share by Manufacturers in 2024

Figure 19. Global Retinal Drugs and Biologics Revenue Share by Manufacturers in 2024

Figure 20. Global 5 and 10 Largest Retinal Drugs and Biologics Players: Market Share by Revenue in Retinal Drugs and Biologics in 2024

Figure 21. Retinal Drugs and Biologics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 22. Global Retinal Drugs and Biologics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 23. North America Retinal Drugs and Biologics Sales Market Share by Country (2020-2031)

Figure 24. North America Retinal Drugs and Biologics Revenue Market Share by Country (2020-2031)

Figure 25. U.S. Retinal Drugs and Biologics Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 26. Canada Retinal Drugs and Biologics Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 27. Europe Retinal Drugs and Biologics Sales Market Share by Country (2020-2031)

Figure 28. Europe Retinal Drugs and Biologics Revenue Market Share by Country (2020-2031)

Figure 29. Germany Retinal Drugs and Biologics Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 30. France Retinal Drugs and Biologics Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 31. U.K. Retinal Drugs and Biologics Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 32. Italy Retinal Drugs and Biologics Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 33. Russia Retinal Drugs and Biologics Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 34. Asia Pacific Retinal Drugs and Biologics Sales Market Share by Region (2020-2031)

Figure 35. Asia Pacific Retinal Drugs and Biologics Revenue Market Share by Region (2020-2031)

Figure 36. China Retinal Drugs and Biologics Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. Japan Retinal Drugs and Biologics Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 38. South Korea Retinal Drugs and Biologics Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. India Retinal Drugs and Biologics Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. Australia Retinal Drugs and Biologics Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. Taiwan Retinal Drugs and Biologics Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. Indonesia Retinal Drugs and Biologics Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Thailand Retinal Drugs and Biologics Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 44. Malaysia Retinal Drugs and Biologics Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 45. Philippines Retinal Drugs and Biologics Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 46. Latin America Retinal Drugs and Biologics Sales Market Share by Country (2020-2031)

Figure 47. Latin America Retinal Drugs and Biologics Revenue Market Share by Country (2020-2031)

Figure 48. Mexico Retinal Drugs and Biologics Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 49. Brazil Retinal Drugs and Biologics Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 50. Argentina Retinal Drugs and Biologics Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 51. Middle East and Africa Retinal Drugs and Biologics Sales Market Share by Country (2020-2031)

Figure 52. Middle East and Africa Retinal Drugs and Biologics Revenue Market Share by Country (2020-2031)

Figure 53. Turkey Retinal Drugs and Biologics Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 54. Saudi Arabia Retinal Drugs and Biologics Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 55. U.A.E Retinal Drugs and Biologics Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 56. Global Sales Market Share of Retinal Drugs and Biologics by Type (2020-2031)

Figure 57. Global Revenue Market Share of Retinal Drugs and Biologics by Type (2020-2031)

Figure 58. Global Retinal Drugs and Biologics Price (USD/MT) by Type (2020-2031)

Figure 59. Global Sales Market Share of Retinal Drugs and Biologics by Application (2020-2031)

Figure 60. Global Revenue Market Share of Retinal Drugs and Biologics by Application (2020-2031)

Figure 61. Global Retinal Drugs and Biologics Price (USD/MT) by Application (2020-2031)

Figure 62. Retinal Drugs and Biologics Value Chain

Figure 63. Channels of Distribution (Direct Vs Distribution)

Figure 64. Bottom-up and Top-down Approaches for This Report

Figure 65. Data Triangulation

Figure 66. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions